LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Carnegie Group Downgrades Zealand Pharma to Hold from Buy, Lifts PT MT
Would you like some more inflation? Our Logo
Zealand Pharma Upsizes Directed Share Offering to $1 Billion Amid Strong Demand MT
Nordic Shares Rose Monday; ALK-Abello Series B Led Increases DJ
Zealand Pharma A/S(CPSE:ZEAL) added to OMX Copenhagen 20 Index CI
Zealand Pharma shares soar on obesity results CF
Europe's STOXX 600 falls as tech, banks drag RE
European shares open lower as tech losses weigh RE
Zealand Pharma Says Petrelintide Drug Reduces Weight in Phase 1b Study MT
Transcript : Zealand Pharma A/S - Special Call
Zealand Pharma's drug reduces weight by 8.6% in early-stage study RE
Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide CI
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Transcript : Zealand Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Zealand Pharma, Boehringer Ingelheim Weight Loss Compound Hits Midstage Endpoints for Liver Fibrosis MT
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL CI
Zealand Pharma Secures EU Panel Backing for Severe Hypoglycemia Treatment MT
Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide CI
Nordic Stocks Declined Thursday; Zealand Pharma Took Biggest Hit DJ
Transcript : Zealand Pharma A/S, Q1 2024 Earnings Call, May 16, 2024
Zealand Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year DJ
Zealand Pharma A/S Approves Appointments to the Board CI
Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle... Our Logo
Zealand Pharma A/S Announces Board Changes CI
Chart Zealand Pharma A/S
More charts
Logo Zealand Pharma A/S
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Employees
270
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
880.00DKK
Average target price
981.33DKK
Spread / Average Target
+11.52%
Consensus
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. News Zealand Pharma A/S
  5. Zealand Pharma, Boehringer Ingelheim Weight Loss Compound Hits Midstage Endpoints for Liver Fibrosis